Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 32 for “"estrogen-receptor positive"”.
-
Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting
… studies have reported response rates for ER positive cancers on neoadjuvant endocrine therapy (NET), with lower toxicity compared to neoadjuvant chemotherapy (NCT). During the first wave of the COVID pandemic, clinician preference for NET increased significantly, buying time for hospital …
-
New molecular approches using AR, FOXA1 and HER2 for outcome classification of estrogen Receptor-Positive (ER+) breast cancers”
Here, we studied new prognostic and predictive easy access strategies in breast cancer (molecular markers), for better classify ER+ breast cancer disease, which might provide additional information and be complementary to the clasical clinical-pathological prediction models.
-
The decision making process in women diagnosed with estrogen receptor-positive breast cancer experiencing side effects related to oral endocrine therapy
… (OET) is standard therapy for millions of estrogen receptor-positive breast cancer survivors (ER+BCS). OET reduces recurrence, mortality, and metastasis. ER+BCS often do not take their OET as recommended due to adverse side effects. The purpose of this dissertation was to develop an …
-
Antiproliferative activities of Euphorbia bicolor (euphorbiaceae) and Maclura pomifera (moraceae) extracts on estrogen receptor-positive and triple-negative breast cancer cell lines
… Recent research has highlighted the transient receptor potential vanilloid 1 (TRPV1) ion channel as a promising target for cancer treatment. This study explores the antiproliferative properties and mechanisms of action of phytochemicals from two native plants, Maclura pomifera and Euphorbia …
-
Comprehensive gene assessment of estrogen receptor positive breast cancers reveals that HER2 positive status plays an important role in resistance to neoadjuvant letrozole
Background The ER positive/ HER2 positive molecular subtype accounts for up to 10% of all breast cancers, these cancers have a worse prognosis than ER positive/ HER2 negative breast cancers. There is considerable evidence that ER positive/ HER2+ positive cancers exhibit resistance to endocrine …
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
… CDK4/6 inhibitors for the treatment of advanced estrogen receptor positive breast cancer. However, three major clinical challenges remain: i) adverse events leading to discontinuation of therapy and ii) lack of reliable biomarkers to identify responsive patients and iii) acquired resistance to …
-
Aminoflavone Inhibits α6-integrin and Growth of Tamoxifen Resistant Breast Cancer
<p>Approximately 40% of estrogen receptor positive (ER+) breast cancer patients develop resistance to standard of care agent tamoxifen, while ER negative (ER-) breast cancer patients are intrinsically resistant to tamoxifen. Resistance often promotes metastasis, recurrence and death. …
-
An exploratory analysis of large health cohort study using Bayesian networks
… results showed for clomid an increased risk of estrogen receptor positive breast cancer (odds ratio 1.52, 95% CI 1.11-2.09) and a decreased risk of estrogen receptor negative breast cancer (odds ratio 0.46, 95% CI 0.22-0.97).
-
Radiation Sensitization of Breast Cancer Cells by Vitamin D Through the Promotion of Autophagic Cell Death
… Studies were extended to the wild type p53, estrogen receptor positive, ZR-75-1 breast cancer cell line. We were able to validate that vitamin D3 does in fact, sensitize ZR-75-1 breast cancer cells to radiation therapy and substantiate that autophagy is the mode of sensitization by vitamin …
-
Analysis of Variant Alleles of Gene Thought to Affect Breast Cancer in a Patient Population from South Carolina
… polymorphism was negatively associated with estrogen receptor positive expression status (OR= 0.33, p-value = 0.001).</p> <p><strong>Conclusions:</strong> Comparisons of significant parameter-locus relationships between the two groups of patients were effective at identifying locus-parameters …
-
Machine learning-driven integration of multimodal data for deciphering breast cancer heterogeneity
… objectives: 1)human epidermal growth factor receptor2 positive/estrogen receptor-positive (HER2+/ER+) BC stratification and prognostic gene signature identification using single genomic data; 2) BC subtyping using multiple genomics data; 3) Graph neural network (GNN) for BC hierarchical …
-
Identification and Characterization of TONSL as an Immortalizing Oncogene
… conjunction with defined oncogenes, resulting in Estrogen Receptor-positive breast adenocarcinomas. Furthermore, we observed that TONSL-amplified breast cancer cells are dependent on TONSL for tumor growth, and these TONSLHigh cells and tumors exhibit an upregulated homologous recombination DNA …
-
Altered estrogen receptor and transforming growth factor pathways in models of estrogen-autonomous and of antiestrogen-resistant MCF-7 human breast cancer cells
… of breast tumors to steroid-autonomous and antiestrogen-resistant phenotypes confounds our ability to treat breast cancer with antiestrogens, the most efficacious hormone treatment used clinically. We developed two models in the MCF-7 cell line, an estrogen receptor-positive human breast cancer …
-
Proteomic Map of ER+ Breast Cancer Cell Cycle
… diagnosed in women, ~70% of cases displaying an estrogen receptor positive (ER+) phenotype. The aim of the present work was to generate a comprehensive overview of the biological mechanisms, molecular pathways and specific proteins involved in cell cycle progression in ER+ breast cancer cells. We …
-
Regulation of the Glucocorticoid Receptor Promoter and Its Prognostic Value in Tamoxifen-Treated ER+ Breast Cancer
Most breast cancers are estrogen receptor positive (ER+) and therefore benefit from endocrine-based therapies such as tamoxifen which impair estrogen signaling. However, resistance is a major clinical concern and ER status alone is insufficient to predict treatment response. As a result, additional …
-
Krūties carcinoma in situ tipai, diagnostika, gydymas ir prognozė /
… therapy, which is recommended for patients with estrogen receptor positive (ER+) ductal carcinoma in situ, The prognosis for breast carcinoma in situ is generally favourable, as early diagnosis and treatment of breast carcinoma in situ results in high survival rates and a low risk of recurrence …
-
Resolving Intra-Tumoral Heterogeneity of Breast Cancer Using Single-Cell Multi-Omics
… on triple-negative breast cancer (TNBC) and estrogen receptor-positive (ER+) breast cancer.</p> <p>In the first part, we applied single-cell RNA sequencing and spatial transcriptomics to profile over 400,000 cells from 101 treatment-naïve TNBC patients. We identified 4 archetypes at the …
-
A Mass Spectrometry-Based Method For Quantification Of Human Metallothionein Isoforms And Usefulness In Biomarker Detection Of Cancers And Metal Toxicity
… cell lines. The malignant cell lines were either estrogen receptor positive (ER+) or estrogen receptor negative (ER-). Three MT isoforms (MT-2, MT-1E, and MT-1X) were quantified in the breast cells. In regards to the ER status of the cells, the ER+ malignant cells had low MT protein levels while …
-
Protein Set for Normalization of Quantitative Mass Spectrometry Data
… cell cycle experiments performed with MCF-7, an estrogen receptor positive breast cancer cell line, and MCF-10A, a non-tumorigenic immortalized breast cell line. The protein set was selected from a list of 3700 proteins identified in the different cellular sub-fractions and cell cycle stages of …
Page 1 of 2